4D Molecular Therapeutics Inc FDMT

US Biotechnology

$10.18 ▲ +1.09% (+$0.11)

⬆️ Above Yest. High 🔥 High Short Interest 🎢 High Beta 🗓️ Earnings Next Week

Open $10.54

Prev Close $10.07

Day Range $9.84 – $10.65

52W Range $4.30 – $14.00

Market Cap $532.17M

Beta 2.70

EPS (TTM) $-2.70

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-12-11
Shares Out.	52,280,000
Website	4dmoleculartherapeutics.com/ ↗
Phone	15105052680
Employees	196
Revenue	$3.0M
Gross Profit	$3.0M
Net Income	-$68.8M
Free Cash Flow	-$129.5M
Total Assets	$512.9M
Total Liabilities	$61.1M
Equity	$451.8M

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

4D Molecular Therapeutics Inc is a publicly traded company under the ticker symbol FDMT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.